Defining the need for local therapy in locally advanced prostate cancer: An appraisal of the MRC PR07 study

Clinical Oncology

Volumn 17, Issue 4, 2005, Pages 217-218

  Mason, Malcolm ^a,b   Warde , P ^a   Sydes, M ^a   Cowan, R ^a   James, N ^a   Kirkbride, P ^a   Langley, R ^a   Latham, J ^a   Moynihan, C ^a   Anderson, J ^a   Millet, J ^a   Nutall, J ^a   Moffat, L ^a   Parulekar, W ^a   Parmar, M ^a  

^a Clinical Trials Group   (Canada)

^b VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; HORMONE;

ADVANCED CANCER; ANDROGEN THERAPY; BONE METASTASIS; BRACHYTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; HORMONAL THERAPY; HUMAN; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE;

ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM STAGING; PROGNOSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 21044453001     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2005.02.013     Document Type: Editorial

References (14)

1. R.M. Galalae G. Kovacs J. Schultze et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer Int J Radiat Oncol Biol Phys 52 2002 81-90
2. E.J. Adams D.J. Convery V.P. Cosgrove et al. Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement Radiother Oncol 70 2004 1-10
3. J. Hiratsuka Y. Jo K. Yoshida et al.Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer Int J Radiat Oncol Biol Phys 59 2004 684-690
4. L.L. Kestin A.A. Martinez J.S. Stromberg et al. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer (see comment) J Clin Oncol 18 2000 2869-2880
5. G.S. Merrick W.M. Butler R.W. Galbreath et al. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer Int J Radiat Oncol Biol Phys 51 2001 41-48
6. Y. Yoshioka T. Nose K. Yoshida et al. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: A retrospective analysis with special focus on tolerance and chronic toxicity Int J Radiat Oncol Biol Phys 56 2003 213-220
7. H. Van Poppel H. Goethuys P. Callewaert et al. Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer Eur Urol 38 2000 329-372
8. K. Sato N. Tsuchiya T. Habuchi et al. Total cystoprostatectomy in the treatment of locally advanced prostate carcinoma Aktuelle Urol 34 2003 259-261
9. Medical Research Council Prostate Cancer Working Party Investigators Group Immediate versus deferred treatment for advanced prostatic cancer; initial results of the Medical Research Council trial Br J Urol 79 1997 235-246
10. M. Roach M. De Silvio C. Lawton et al. Neoadjuvant hormonal therapy (NHT) with whole-pelvic (WP) radiotherapy (RT) improves progression-free survival (PFS): RTOG (Radiation Therapy Oncology Group) 9413, a phase III randomized trial Proc Am Assoc Cancer Res 2002 711
11. M. Roach M. DeSilvio C.R. Thomas et al. Progression free survival (PFS) after whole-pelvic (WP) vs mini-pelvic (MP) or prostate only (PO) radiotherapy (RT): A subset analysis of RTOG 9413, a Phase III prospective randomized trial using neoadjuvant and concurrent (N&CHT) Int J Radiat Oncol Biol Phys 60 2004 S264-S265
12. I. Roberts D. Yates P. Sandercock et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): Randomised placebo-controlled trial (see comment) Lancet 364 2004 1321-1328
13. G.L. Anderson M. Limacher A.R. Assaf et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial (see comment) JAMA 291 2004 1701-1712
14. J. Barber M.D. Mason Radiotherapy for T3 prostate cancer In: W.G. Bowsher editor Challenges in prostate cancer 2000 Blackwell Science Oxford